Abstract
The proximal DNA damage response kinase ATM is frequently inactivated in human malignancies. Germline mutations in the ATM gene cause Ataxia-telangiectasia (A-T), characterized by cerebellar ataxia and cancer predisposition. Whether ATM deficiency impacts on tumor initiation or also on the maintenance of the malignant state is unclear. Here, we show that Atm reactivation in initially Atm-deficient B- and T cell lymphomas induces tumor regression. We further find a reduced T cell abundance in B cell lymphomas from Atm-defective mice and A-T patients. Using T cell-specific Atm-knockout models, as well as allogeneic transplantation experiments, we pinpoint impaired immune surveillance as a contributor to cancer predisposition and development. Moreover, we demonstrate that Atm-deficient T cells display impaired proliferation capacity upon stimulation, due to replication stress. Altogether, our data indicate that T cell-specific restoration of ATM activity or allogeneic hematopoietic stem cell transplantation may prevent lymphomagenesis in A-T patients.
| Original language | English |
|---|---|
| Journal | Leukemia |
| Volume | 34 |
| Issue number | 3 |
| Pages (from-to) | 771-786 |
| Number of pages | 16 |
| ISSN | 0887-6924 |
| DOIs | |
| Publication status | Published - 01.03.2020 |
Funding
Acknowledgements This work was supported through the Cologne Center for Genomics of the University of Cologne. We thank Prof. Peter Nürnberg, Dr. Janine Altmüller and Dr. Graziella Bosco (University of Cologne, Germany) for help with RNA-and whole exome sequencing. Financial support This work was supported by the Volkswagen-stiftung (Lichtenberg Program, HCR), the Deutsche For-schungsgemeinschaft (KFO-286, LPF and HCR, JA 2439/1-1 to RDJ), the Bundesministerium für Bildung und Forschung (SMOOSE, HCR), the German federal state NRW (EFRE initiative, LS-1-1-030a, HCR), the Else Kröner-Fresenius Stiftung (EKFS-2014-A06, HCR, 2016-Kolleg-19 to RDJ), the Deutsche Krebshilfe (111724, HCR) and the Jose Carreras Stiftung (DJCLS-R12/26, LPF and HCR). Conflict of interest HCR received consulting fees from Abbvie, AstraZeneca, Vertex, and Merck and research funding from Gilead. The remaining authors declare that they have no conflict of interest.